Welcome to our dedicated page for Steris Plc SEC filings (Ticker: STE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
STERIS plc filings document material events for an Ireland-incorporated operating company with ordinary shares traded as STE on the New York Stock Exchange. Recent Form 8-K reports cover results of operations and financial condition, attached earnings releases, director appointments and retirements, officer transition arrangements, and compensation-related amendments.
The filing record also identifies STERIS securities registered under Section 12(b), including ordinary shares and NYSE-listed senior notes due 2031 and 2051. These disclosures frame the company’s capital structure, governance actions, executive-compensation matters, and periodic operating-result announcements for its infection-prevention and life sciences business.
STERIS plc senior vice president, general counsel and secretary John Adam Zangerle reported an open-market sale of 1,419 Ordinary Shares at $209.28 per share. After this transaction, he directly holds 35,259 Ordinary Shares.
As of June 15, 2026, 8,239 of these Ordinary Shares are restricted, with restrictions scheduled to lapse in stages between June 2, 2027 and June 4, 2029.
STERIS plc reported Form 144 resale notices for restricted stock lapses. The filing lists restricted stock lapses tied to equity compensation: 820 shares dated 06/01/2026 and 599 shares dated 06/02/2026. The entries appear under "Securities To Be Sold."
STERIS plc is asking shareholders to vote at its July 31, 2026 annual general meeting in Dublin on eight proposals, including electing nine directors, ratifying Ernst & Young as auditors, an advisory say-on-pay vote, and renewing authorities to issue shares and opt out of Irish pre-emption rights.
The proxy highlights a record fiscal 2026, with revenue up 8.7% to $5,935.9 million and net income rising to $782.3 million, or $7.93 per diluted share. Adjusted net income reached $1,003.4 million, or $10.17 per diluted share, and free cash flow grew 24.9% to $982.9 million. Operating cash flow increased 16.8% to $1,341.4 million.
The Board stresses strong governance practices, broad director independence, and a pay-for-performance philosophy. In fiscal 2026, 90.3% of CEO Daniel Carestio’s compensation was variable, with his annual incentive paying out $1,725,007, or 125.1% of target, based entirely on financial metrics. Shareholders of record at June 2, 2026, with 97,457,680 ordinary shares outstanding, are encouraged to vote by proxy.
STERIS plc senior executive reports routine tax withholding transaction. On June 4, 2026, Sr. VP and General Counsel John Adam Zangerle had 401 ordinary shares withheld at $212.24 per share to cover taxes on 1,376 restricted shares that vested that day, rather than selling shares in the market.
After this withholding, he directly holds 36,678 ordinary shares, including 8,239 restricted shares as of June 8, 2026. The remaining restricted shares are scheduled to lapse in stages through June 4, 2029, reflecting ongoing equity-based compensation.
STERIS plc reported that V.P. & Corporate Treasurer Renato Tamaro had 65 Ordinary Shares withheld on June 4, 2026 as a tax-withholding disposition tied to a restricted share vesting. The 65 shares came from 221 restricted shares that vested that day and were valued at the NYSE closing price on June 4, 2026. Following this withholding, Tamaro directly holds 6,194 Ordinary Shares, of which 1,405 remain restricted. These restrictions are scheduled to lapse in tranches between June 2, 2027 and June 4, 2029.
STERIS plc senior vice president Julia Madsen reported a routine tax-withholding transaction tied to vesting equity awards. On June 4, 2026, 195 ordinary shares were disposed of at $212.24 per share to cover taxes due on 542 restricted shares that vested that day.
After this withholding, Madsen directly holds 12,257 ordinary shares of STERIS, including 4,190 restricted shares as of June 8, 2026. These restricted shares are scheduled to lapse in tranches between June 2, 2027 and June 4, 2029.
STERIS plc SVP & GM, AST Kenneth E. Kohler reported a routine tax-related share disposition. On June 4, 2026, 150 ordinary shares were withheld from 513 restricted shares that vested, to cover taxes based on the NYSE closing price of $212.24 per share. After this, he directly holds 11,332 ordinary shares, including 3,972 restricted shares scheduled to lapse between 2027 and 2029.
STERIS plc senior executive Mary Clare Fraser reported a routine tax-withholding transaction related to restricted share vesting. On June 4, 2026, 600 ordinary shares were withheld at $212.24 per share to cover taxes on 1,360 restricted shares that vested that day. After this tax-withholding disposition, she directly owns 13,716 ordinary shares, including 5,359 restricted shares. The restricted shares are scheduled to lapse in stages between June 2027 and June 2029, reflecting ongoing equity-based compensation rather than an open-market sale.
STERIS plc President and CEO Daniel A. Carestio reported a net sale of 4,428 Ordinary Shares in open‑market transactions. He sold 3,054 shares at $214.64 on June 4, 2026 and 1,374 shares at $212.00 on June 5, 2026.
On June 4, 2026, 1,889 shares were withheld to cover taxes on 4,283 restricted shares that vested, a non‑market tax-withholding disposition. After these transactions, he directly owns 63,647 Ordinary Shares. As of June 8, 2026, 39,893 of these shares remain restricted and are scheduled to vest in tranches through June 4, 2029.